Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
A combination therapy of nivolumab plus ipilimumab (NIVO + IPI) continues to confer survival benefit and durable response over 30 months of follow-up compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to updated results of CheckMate 214 presented at ASCO Genitourinary Cancers Symposium (GUCS) 2019.
Use of axitinib in the neoadjuvant setting appears to result in weight loss, with notable reductions in skeletal muscle and subcutaneous adipose tissue in patients with localized renal cell carcinoma, a recent study has shown.
Nivolumab plus ipilimumab significantly improves overall survival (OS) vs sunitinib in patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC), according to results of the first-line CheckMate 214 study presented at the European Society for Medical Oncology (ESMO) 2017 Congress held in Madrid, Spain.
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.